Willig, J.B.; de Couto, N.M.G.; Vianna, D.R.B.; Mariot, C.d.S.; Gnoatto, S.C.B.; Buffon, A.; Pilger, D.A.
Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy. Pharmaceuticals 2023, 16, 586.
https://doi.org/10.3390/ph16040586
AMA Style
Willig JB, de Couto NMG, Vianna DRB, Mariot CdS, Gnoatto SCB, Buffon A, Pilger DA.
Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy. Pharmaceuticals. 2023; 16(4):586.
https://doi.org/10.3390/ph16040586
Chicago/Turabian Style
Willig, Julia Biz, Nádia Miléo Garcês de Couto, Débora Renz Barreto Vianna, Camila da Silveira Mariot, Simone Cristina Baggio Gnoatto, Andréia Buffon, and Diogo André Pilger.
2023. "Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy" Pharmaceuticals 16, no. 4: 586.
https://doi.org/10.3390/ph16040586
APA Style
Willig, J. B., de Couto, N. M. G., Vianna, D. R. B., Mariot, C. d. S., Gnoatto, S. C. B., Buffon, A., & Pilger, D. A.
(2023). Betulinic Acid-Brosimine B Hybrid Compound Has a Synergistic Effect with Imatinib in Chronic Myeloid Leukemia Cell Line, Modulating Apoptosis and Autophagy. Pharmaceuticals, 16(4), 586.
https://doi.org/10.3390/ph16040586
